Biotechnology company and drug delivery platform
innovator Lexaria Bioscience
(CSE: LXX) (OTCQX: LXRP) today announced a multi-faceted expansion of
its relationship with Hill Street Beverage Company Inc. (TSX.V: BEER).
According to the update, the companies have entered into a 10-year Joint
Manufacturing Partnership (“JMP”) to produce DehydraTECH(TM) commercial
products under a new brand, which will be announced. The JMP will produce
processed THC cannabis and/or CBD hemp powder for new consumer products under
categories including, among others, tablets, capsules, or packets for sale in
Canada and for export where permitted. Similar powders as a bulk ingredient for
manufacturing processes will also be produced under the JMP for sale to other
licensed producers seeking to use Lexaria’s advanced infusion technologies to
create their own products for sale within Canada. “The new relationship between
Hill Street Beverages, One Leaf, and Lexaria Bioscience marks the beginning of
an unprecedented opportunity to deliver outstanding consumer experiences to
cannabis consumers,” Lexaria Bioscience CEO Chris Bunka said in the news
release. “We are delighted to be working with the astute branding and cannabis
expertise of the Hill Street/OneLeaf alliance team and believe that Canadian
and global cannabis consumers will benefit greatly.”
To view the full press release, visit http://ibn.fm/L0q3s
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. licenses disruptive,
patented-delivery technology that promotes healthier ingestion methods, lower
overall dosing and higher effectiveness of lipophilic active molecules. Lexaria
has multiple patents pending in over 40 countries around the world and has
patents granted in the United States and Australia for utilization of its
DehydraTECH delivery technology. Lexaria’s technology provides increases in
intestinal absorption rates, more rapid delivery to the bloodstream, and
important taste-masking benefits for orally administered bioactive molecules
including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. For more information, visit the
company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment